% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Jan 20, 2013 1:56 PM Flag

    GU Cancers Symposium 2/14 /13


    This from Poster Session A:

    Abstract # 58 : Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. ( D13 )
    Paul G. Corn - The University of Texas MD Anderson Cancer Center

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$

      What makes this abstract particularly compelling is that Dr Korn published in the BJC in October 2012:

      "Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials"

      ...and has apparently concluded that a metabolite of bone turnover (BAP) may be predictive of overall survival in advanced mCRPC. This presentation could provide some real entertainment value for Cabo.

5.605+0.195(+3.60%)11:03 AMEDT